XtalPi Holdings (2228) H2 2025 earnings summary

Executive summary

• Achieved first full-year profitability in 2025, with net profit of RMB 134.6 million, reversing a prior loss of RMB 1,514.9 million, driven by 201% revenue growth to RMB 803 million and operational improvements.

• Significant expansion in customer base, including 17 of the world's top 20 pharma companies, and successful entry into new verticals such as consumer health and new materials.

• Major technological advancements in AI, robotics, and multi-agent systems, driving efficiency and innovation across R&D workflows and reinforcing industry leadership.

• Expanded global footprint, secured major collaborations, and advanced multiple innovative drug pipelines to clinical or IND-enabling stages.

Financial highlights

• Revenue rose to RMB 803 million in 2025 from RMB 266 million in 2024, a 201% increase year-over-year.

• Net profit reached RMB 134.6 million, compared to a loss of RMB 1,514.9 million in 2024.

• Adjusted net profit (non-IFRS) was RMB 258 million, up from a loss of RMB 457 million.

• Cash and equivalents plus deposits and financial assets totaled RMB 7,069 million as of December 31, 2025, up 126% year-over-year.

• Operating profit was RMB 55.2 million in 2025, reversing an operating loss of RMB 684.2 million in 2024.

Outlook and guidance

• Continued expansion into consumer health, new materials, agriculture, photovoltaics, and advanced chemicals, with plans to further leverage AI-driven platforms for growth.

• Ongoing investment in AI, robotics, and data platforms to sustain innovation and operational efficiency.

• No final dividend recommended for 2025; focus remains on reinvestment and platform scaling.